Buy
Strong Buy
Buy
Hold
Sell
Strong Sell
0
3
3
0
0
OYSTER P PHARMA INC Share · US69242L1061 · OYST (XNAS) — real-time quotes, company data, dividends, fundamentals, and AI-powered portfolio analysis on MoneyPeak
AI-Powered Analysis
Fundamental Analysis
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of OYSTER P PHARMA INC
Analyst Grade Summary
No Price
Company Profile for OYSTER P PHARMA INC Share
As of January 3, 2023, Oyster Point Pharma, Inc. was acquired by Viatris Inc. Oyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States. The company's product candidate is TYRVAYA, a nicotinic acetylcholine receptor agonist for the treatment of signs and symptoms of dry eye disease. It is also developing TYRVAYA that is in Phase II clinical trial for the treatment of for neurotrophic keratopathy. The company was incorporated in 2015 and is headquartered in Princeton, New Jersey.
Company Data
Name OYSTER P PHARMA INC
Company Oyster Point Pharma, Inc.
Symbol OYST
Website
https://www.oysterpointrx.com
Primary Exchange 
NASDAQ
NASDAQ
ISIN US69242L1061
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Jeffrey Nau
Country United States of America
Currency USD
Employees 0,3 T
Address 202 Carnegie Ctr Ste 109, 08540 Princeton
IPO Date 2019-10-31
Ticker Symbols
| Name | Symbol |
|---|---|
| NASDAQ | OYST |
More Shares
Investors who hold OYSTER P PHARMA INC also have the following shares in their portfolio:
